首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Pharmacodynamics and Medicinal Chemistry of an External Chinese Herbal Formula for Mammary Precancerous Lesions
【2h】

Pharmacodynamics and Medicinal Chemistry of an External Chinese Herbal Formula for Mammary Precancerous Lesions

机译:外用中草药配方治疗乳腺癌前病变的药效学和药物化学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ruyan Neixiao Cream (RYNXC) is a traditional Chinese herbal formula for treating mammary precancerous disease. This study was carried out to investigate in vivo anticancer effect of RYNXC and multiple constituents. 32 virginal Sprague-Dawley rats were randomly divided into blank control group (BC), mammary precancer models group (MODEL), tamoxifen group (TAM), and Ruyan Neixiao Cream group (RYNXC). TAM was intervened by tamoxifen; RYNXC was intervened by Ruyan Neixiao Cream. The chromatographic separation was performed by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS). RYNXC showed significant improvement in erythrocyte aggregation index (EAI), hematocrit (HCT), fibrinogen (FIB), spleen coefficient, and uterus coefficient compared with MODEL. In RYNXC and TAM groups, atypical hyperplasia was observed in pathological mammary tissues; meanwhile in MODEL group, ductal carcinoma was observed in situ. Moreover, fifteen compounds were characterized according to HPLC-MS data, including organic acids, tannin, alkaloid, volatile oil, anthraquinones, and flavonoids. The study suggests that RYNXC was an effective Chinese herbal formula for mammary precancerous lesions and provides a scientific basis for the quality standard and the pharmacology of RYNXC. It will be beneficial to the future clinical application of RYNXC.
机译:乳盐内消霜(RYNXC)是治疗乳癌前期疾病的传统中草药配方。进行该研究以研究RYNXC和多种成分的体内抗癌作用。将32只Sprague-Dawley原始大鼠随机分为空白对照组(BC),乳腺癌模型组(MODEL),他莫昔芬组(TAM)和乳言内消霜组(RYNXC)。 TAM被他莫昔芬干预; RYNXC受到了Ruyan Neixiao Cream的干预。色谱分离是通过高效液相色谱(HPLC)结合质谱(MS)进行的。与MODEL相比,RYNXC在红细胞聚集指数(EAI),血细胞比容(HCT),纤维蛋白原(FIB),脾脏系数和子宫系数方面有显着改善。在RYNXC和TAM组中,在病理性乳腺组织中观察到非典型增生。同时在MODEL组中,原位观察到导管癌。此外,根据HPLC-MS数据表征了15种化合物,包括有机酸,丹宁酸,生物碱,挥发油,蒽醌和类黄酮。研究表明,RYNXC是治疗乳腺癌癌前病变的有效中草药配方,并为RYNXC的质量标准和药理学提供了科学依据。它将对RYNXC的未来临床应用有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号